Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™
Ocugen, Inc. (OCGN)
Company Research
Source: GlobeNewswire
MALVERN, Pa., June 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVAXIN™ to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets. “We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” said J.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccine
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OcugenGlobeNewswire
- OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors Can Join the Class Action Lawsuit!Accesswire
- Ocugen, Inc. (NASDAQ: OCGN) had its price target raised by analysts at Chardan Capital from $4.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmAccesswire
- OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors Can Join the Class Action Lawsuit!Accesswire
OCGN
Earnings
- 11/9/23 - Beat
OCGN
Sec Filings
- 4/18/24 - Form S-3
- 4/18/24 - Form S-8
- 4/17/24 - Form 4
- OCGN's page on the SEC website